Enanta Pharmaceuticals Reports 15.4% Revenue Growth in Q2 Fiscal 2026

Enanta Pharmaceuticals, Inc. reported its financial results for the second quarter of fiscal 2026, revealing a total revenue of $17.2 million for the three months ended March 31, 2026, compared to $14.9 million for the same period in 2025. The increase in revenue, primarily driven by higher reported sales of AbbVie’s MAVYRET/MAVIRET, reflects a 15.4% year-over-year growth. For the six months ended March 31, 2026, total revenue reached $35.8 million, up from $31.9 million in the prior year. Despite the revenue growth, the company reported a net loss of $13.1 million for the quarter, an improvement from a net loss of $22.6 million in the same quarter last year.

Operating expenses for the second quarter decreased significantly to $29.0 million from $39.5 million in the prior year, largely due to a reduction in research and development costs, which fell to $19.4 million from $28.1 million. This decline was attributed to the timing of clinical trials in the company's respiratory syncytial virus (RSV) programs. General and administrative expenses also decreased to $9.6 million from $11.4 million, primarily due to lower stock-based compensation expenses. The company’s total operating loss for the quarter was $11.9 million, compared to a loss of $24.5 million in the same period last year.

Enanta's balance sheet as of March 31, 2026, showed total assets of $314.7 million, an increase from $280.7 million at the end of the previous fiscal year. The company’s cash, cash equivalents, and marketable securities totaled $227.0 million, providing a solid liquidity position to fund ongoing operations and development programs. The company continues to focus on its wholly-owned programs in virology and immunology, with significant investments in clinical trials for its RSV candidates, including zelicapavir and EDP-323, as well as immunology programs targeting type 2 inflammatory diseases.

In terms of strategic developments, Enanta entered into a royalty sale agreement with OMERS in April 2023, receiving $200 million in exchange for 54.5% of future royalty payments from MAVYRET/MAVIRET sales. This agreement has been recorded as a liability on the balance sheet and will be amortized over the term of the agreement. The company anticipates that its existing financial resources will be sufficient to fund operations into fiscal 2029, although it may seek additional funding through equity offerings or collaborations to support its research and development efforts.

Looking ahead, Enanta expects to continue advancing its clinical programs while managing operating expenses. The company remains focused on its strategic goals, including the potential for new product launches and geographic expansion, as it navigates the complexities of the biotechnology landscape. The outlook remains cautiously optimistic, with the company planning to provide updates on its clinical trials and development paths in the coming quarters.